REFERENCES
- Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothe-lial growth factor in ovarian cancer: inhibition of ascites forma-tion by immunoneutralization. Am J Pathol. 1998; 153: 1249–1256.
- Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, Jaffe RB. Vascular endothelial growth factor immunoneutraliza-tion plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol. 2002; 161: 1917–1924.
- Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic On-cology Group Study. J Clin Oncol. 2007; 25: 5165–5171.
- Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Ka-plan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205–216.
- Guppy AE, Nelstrop AE, Foster T, Agarwal R, Seckl MJ, Rustin GJ. A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer. Br J Cancer. 2004; 90: 810–814.
- Rustin GJ. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol. 2003; 21( 10 Suppl): 187s-193s.
- Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the East-ern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649–655.
- Bast RC, Thigpen JT, Arbuck SG, Basen-Engquist K, Burke LB, Freedman R, et al. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop. Gy-necol Oncol. 2007; 107: 173–176.
- Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, flu-orouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335–2342.
- Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. A randomized phase III trial of pacli-taxel versus paclitaxel plus bevacizumab as first-line therapy for locallly recurrent or metastatic breast cancer. J Clin Oncol. 2005; 23: 792–799.
- Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, et al. Outcomes for elderly, advanced-stage non-small cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008; 26 (1): 60–65.
- Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008; 26 (1): 76–82.
- Cannistra SA, Matulonis U, Penson R, Hambleton J, Du-pont J, Mackey H, et al. Phase II study of bevacizumab in Patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007; 25: 5180–5186.
- Monk BJ, Han E, Josephs-Cowan CA, Pugmire G, Burger RA. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithe-lial ovarian cancer. Gynecol Oncol. 2006; 102: 140–144.
- Wright JD, Hagemann A, Rader JS, Viviano D, Gibb RK, Norris L, et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospec-tive analysis. Cancer. 2006; 107: 83–89.
- Wright JD, Secord AA, Numnum TM, Rocconi RP, Pow-ell MA, Berchuck A, et al. A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. Int J Gynecol Cancer. 2008; 18 (3): 400–406.
- Cohn DE, Valmadre S, Resnick KE, Eaton LA, Copeland LJ, Fowler JM. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol. 2006; 102: 134–139.
- Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fal-lopian tube cancer: a trial of the Chicago, PMH, and California phase II Consortia. Gynecol Oncol. 2008; 110 (1): 49–55.
- Aghajanian C. The role of bevacizumab in ovarian can-cer—an evolving story. Gynecol Oncol. 2006; 102: 131–133.
- Frumovitz M, Sood AK. Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic ma-lignancies. Gynecol Oncol. 2007; 104: 768–778.